Growth & profitability
- Revenue has grown 13.2% per year over the past 5 years.
- Operating margin has expanded, at -230.9% in the latest year.
CELU Financials Celularity Inc
7 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $27M | -$92M | 24.4% | -230.9% | — | — | $6M |
| 2024 | $54M | -$58M | 72.4% | -70.7% | -$7M | — | $738000 |
| 2023 | $23M | -$196M | 29.7% | -844.4% | -$40M | — | $227000 |
| 2022 | $18M | $14M | -9.4% | -142.4% | -$143M | — | $14M |
| 2021 | $21M | -$100M | 54.8% | -511.2% | -$116M | — | $37M |
| 2020 | $14M | -$208M | 65.5% | -1064.0% | -$91M | — | $54M |
| 2019 | — | $6M | — | — | — | — | $917007 |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Dec '25 | $4M | -$24M | -79.7% | -537.5% | — | — | $6M |
| Sep '25 | $5M | -$23M | 26.1% | -244.1% | — | — | $120000 |
| Jun '25 | $6M | -$25M | 8.6% | -276.6% | — | — | $863000 |
| Mar '25 | $11M | -$20M | 68.9% | -91.8% | — | — | $293000 |
| Dec '24 | $18M | -$13M | 59.5% | -51.2% | $2M | — | $738000 |
| Sep '24 | $9M | -$16M | 58.2% | -124.0% | -$144000 | — | $133000 |
| Jun '24 | $12M | -$6M | 82.5% | -84.0% | -$3M | — | $467000 |
| Mar '24 | $15M | -$22M | 88.8% | -50.2% | -$4M | — | $2M |
| Dec '23 | $12M | $10M | 20.7% | 109.9% | -$5M | — | $227000 |
| Sep '23 | $4M | -$94M | 4.9% | -2621.7% | -$9M | — | $273000 |
| Jun '23 | $3M | -$48M | 72.7% | -1445.7% | -$11M | $34M | $3M |
| Mar '23 | $4M | -$64M | 49.1% | -1623.1% | -$15M | $36M | $9M |
| Dec '22 | $4M | $24M | -27.1% | 423.5% | -$30M | — | $14M |
| Sep '22 | $4M | $5M | -74.4% | -136.5% | -$39M | — | $43M |
| Jun '22 | $4M | $48M | 15.8% | 110.6% | -$38M | — | $38M |
| Mar '22 | $6M | -$63M | 32.2% | -701.2% | -$36M | — | $48M |
| Dec '21 | $5M | -$4M | 4.0% | -307.9% | -$34M | — | $37M |
| Sep '21 | $11M | $50M | 78.2% | 102.6% | -$36M | — | $73M |
| Jun '21 | $3M | -$64M | 55.0% | -1895.9% | -$20M | — | $211 |
| Mar '21 | $3M | -$82M | 53.3% | -1669.0% | -$27M | — | $28654 |
Valuation over time
How the market has priced CELU against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has fallen from 1.3× (Mar '23) to 1.1× (Jun '23).
- The price-to-sales ratio has fallen from 1.0× (Mar '23) to 0.7× (Jun '26).
P/E
P/S
Frequently asked questions
Is CELU growing its revenue and profit?
Over the past 5 years, Celularity Inc's revenue has grown 13.2% per year. These are computed facts, not advice.
How much debt does CELU have?
As of FY2025, Celularity Inc reported — of total debt against $6M of cash.
What is CELU's profit margin?
In FY2025, gross margin was 24.4%, operating margin -230.9%, and net margin -345.4%.
What is CELU's P/E ratio?
As of Jun '26, Celularity Inc traded at a price-to-earnings ratio of about 1.1× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.